COMMUNIQUÉS West-GlobeNewswire
-
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
09/07/2026 -
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
09/07/2026 -
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
09/07/2026 -
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
09/07/2026 -
Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine
09/07/2026 -
Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care
09/07/2026 -
Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
09/07/2026 -
UREVO Wins Red Dot Award 2026 for AI-Powered Wireless Recovery Boots, Recognized for Real-Time, AI-Adaptive Recovery
09/07/2026 -
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
09/07/2026 -
TOMI Reports 124% Increase in Preliminary Second Quarter Revenue; Preliminary Six Months Revenue Combined with Open Orders Surpass Full Year 2025 Revenue
09/07/2026 -
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
09/07/2026 -
NTG Nordic Transport Group A/S - H1 2026 Conference Call
09/07/2026 -
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
09/07/2026 -
Roche receives CE Mark for blood test to identify tuberculosis infection
09/07/2026 -
Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges
09/07/2026 -
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
09/07/2026 -
Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.
09/07/2026 -
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
09/07/2026 -
Outliyr's Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
09/07/2026
Pages